Merck’s Winrevair granted FDA approval to treat pulmonary arterial hypertension in adults
Merck and Co’s – known as MSD outside the US and Canada – Winrevair (sotatercept-csrk) has been approved by the US Food and Drug Administration to treat adults with pulmonary arterial hypertension (PAH). Affecting approximately 500 to 1,000 people in the …